ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

PCVX Vaxcyte Inc

65.96
1.41 (2.18%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Vaxcyte Inc PCVX NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
1.41 2.18% 65.96 09:00:00
始値 安値 高値 終値 前日終値
66.48 65.46 67.08 65.96 64.55
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/0305:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
2024/3/0511:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0511:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0511:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0422:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
2024/3/0206:02EDGAR2Form 144 - Report of proposed sale of securities
2024/3/0206:00EDGAR2Form 144 - Report of proposed sale of securities
2024/2/2806:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2806:02EDGAR2Form 8-K - Current report
2024/2/2806:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
2024/2/2106:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1606:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
2024/2/0607:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0607:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0308:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
2024/2/0206:07EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0206:06EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0206:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
2024/2/0107:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/2/0107:19EDGAR2Form 8-K - Current report
2024/1/3113:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
2024/1/3106:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/3106:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
2024/1/2922:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
2024/1/1706:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
2024/1/0506:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
2024/1/0306:04EDGAR2Form 144 - Report of proposed sale of securities
2024/1/0306:03EDGAR2Form 144 - Report of proposed sale of securities
2023/12/1206:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0806:15EDGAR2Form 144 - Report of proposed sale of securities
2023/12/0606:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0508:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
2023/12/0206:12EDGAR2Form 144 - Report of proposed sale of securities
2023/11/3006:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/3006:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/11/2822:32EDGAR2Form 8-K - Current report
2023/11/2822:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
2023/11/2806:05EDGAR2Form 8-K - Current report
2023/11/2806:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
2023/11/0922:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
2023/11/0706:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0706:07EDGAR2Form 8-K - Current report
2023/11/0706:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
2023/11/0405:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0205:07EDGAR2Form 144 - Report of proposed sale of securities
2023/11/0105:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
2023/10/1922:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
2023/10/1921:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..

最近閲覧した銘柄

Delayed Upgrade Clock